Compounded Tirzepatide 60mg 99.3% purity peptide

A next-generation Compounded Tirzepatide (GLP-1/GIP) injection, combining dual pathways for appetite regulation and metabolic improvement, designed to support significant progress in weight care and health goals.

Compounded Tirzepatide (GLP-1/GIP) is a once-weekly injectable therapy that mimics dual incretin hormones, potentially offering stronger support for appetite regulation and metabolic balance than GLP-1 alone.

This dual-acting option combines two pathways in one medication, giving patients a next-generation therapy under professional guidance in a convenient, accessible setting.

TR2 60mg — Dual Incretin Receptor Agonist

Most incretin-based research compounds work through a single receptor. TR2 works through two. This 39-amino-acid synthetic peptide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously — two distinct arms of the incretin signaling system that, when engaged together, produce metabolic effects that neither achieves on its own.

The rationale is straightforward: GLP-1 receptor activation drives glucose-dependent insulin secretion and appetite-regulating signals from the hypothalamus. GIP receptor activation adds something GLP-1 cannot reach — direct metabolic signaling in adipose tissue and bone through receptor populations that GLP-1 agonists simply do not engage. Preclinical data suggests the combined effect is greater than additive.

Why dual agonism matters

GIP and GLP-1 both signal through cAMP-mediated pathways in pancreatic beta cells, but their downstream effects diverge substantially. GIP receptors are expressed in adipose tissue and the central nervous system at densities that GLP-1 receptors are not. This means a dual agonist like TR2 engages metabolic control points — particularly in fat tissue signaling and energy balance — that selective GLP-1 compounds leave untouched.

Preclinical models have shown amplified insulinotropic responses when both receptor systems are active, with effects on glucagon regulation, beta cell function, and body composition that exceed what either pathway delivers independently.

Specifications

Preclinical research highlights

Dual incretin receptor activation has been characterized in preclinical models for synergistic effects on pancreatic beta cell function, insulin secretion kinetics, and glucagon regulation. Additional research has examined glucose homeostasis, energy expenditure, appetite regulation, and body composition outcomes — with the dual approach consistently outperforming single-receptor activation in these models.

How TR2 compares to SM1

SM1 is a selective GLP-1 receptor agonist — 31 amino acids, one receptor target. TR2 is 39 amino acids and hits both GIP and GLP-1 receptors. The comparative research literature documents meaningfully different metabolic profiles between the two approaches, particularly in adipose tissue signaling. Both are available from Heritage Labs USA for researchers interested in the incretin axis.

Frequently paired with

• Cagrilintide 5mg — Amylin analog acting through separate hindbrain satiety circuits
• MOTS-C 10mg — Mitochondrial peptide for AMPK-mediated metabolic studies
• L-Carnitine 600mg — Mitochondrial fatty acid transport research

Quality and testing

Third-party tested with batch-specific Certificates of Analysis available for every order.

Storage

• Lyophilized: Store at -20°C for long-term stability
• Reconstituted: 2-8°C, use within 30 days